YU3501A - Coadministration of acat and mmp inhibitors for the treatment of atherosclerotic lesions - Google Patents

Coadministration of acat and mmp inhibitors for the treatment of atherosclerotic lesions

Info

Publication number
YU3501A
YU3501A YU3501A YU3501A YU3501A YU 3501 A YU3501 A YU 3501A YU 3501 A YU3501 A YU 3501A YU 3501 A YU3501 A YU 3501A YU 3501 A YU3501 A YU 3501A
Authority
YU
Yugoslavia
Prior art keywords
coadministration
acat
mmp inhibitors
treatment
atherosclerotic lesions
Prior art date
Application number
YU3501A
Other languages
Serbo-Croatian (sh)
Inventor
Thomas Michael Andrew Bocan
Original Assignee
Warner-Lambert Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner-Lambert Company filed Critical Warner-Lambert Company
Publication of YU3501A publication Critical patent/YU3501A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

This invention is the coadministration of ACAT and MMP inhibitors for the reduction of both the macrophage and smooth muscle cell component of atherosclerotic lesions, thus impairing the expansion of existing lesions and the development of new lesions and for the prevention of plaque rupture and the promotion of lesion regression in a mammal.
YU3501A 1998-07-21 1999-06-18 Coadministration of acat and mmp inhibitors for the treatment of atherosclerotic lesions YU3501A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US9363998P 1998-07-21 1998-07-21

Publications (1)

Publication Number Publication Date
YU3501A true YU3501A (en) 2005-06-10

Family

ID=22239992

Family Applications (1)

Application Number Title Priority Date Filing Date
YU3501A YU3501A (en) 1998-07-21 1999-06-18 Coadministration of acat and mmp inhibitors for the treatment of atherosclerotic lesions

Country Status (25)

Country Link
EP (1) EP1098662A2 (en)
JP (1) JP2002521328A (en)
KR (1) KR20010083134A (en)
CN (1) CN1310629A (en)
AP (1) AP2001002035A0 (en)
AU (1) AU4701799A (en)
BG (1) BG105162A (en)
BR (1) BR9912296A (en)
CA (1) CA2335062A1 (en)
CZ (1) CZ2001126A3 (en)
EA (1) EA200100153A1 (en)
EE (1) EE200100046A (en)
HR (1) HRP20010055A2 (en)
HU (1) HUP0102880A3 (en)
ID (1) ID30030A (en)
IL (1) IL140982A0 (en)
IS (1) IS5809A (en)
NO (1) NO20010291D0 (en)
OA (1) OA11584A (en)
PL (1) PL346011A1 (en)
SK (1) SK502001A3 (en)
TR (1) TR200100205T2 (en)
WO (1) WO2000004892A2 (en)
YU (1) YU3501A (en)
ZA (1) ZA200100294B (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20020050257A (en) * 1999-11-05 2002-06-26 로즈 암스트롱, 크리스틴 에이. 트러트웨인 Prevention of Plaque Rupture by ACAT Inhibitors
DOP2000000107A (en) 1999-12-01 2002-09-16 Agouron Pharmaceutical Inc COMPOUNDS, COMPOSITIONS AND METHODS TO STIMULATE THE GROWTH AND LENGTH OF NEURONS
AU2268401A (en) * 1999-12-17 2001-06-25 Versicor Inc Novel succinate compounds, compositions and methods of use and preparation
EP1314423A4 (en) * 2000-09-01 2004-05-19 Sankyo Co Medicinal compositions
GB0100761D0 (en) 2001-01-11 2001-02-21 Biocompatibles Ltd Drug delivery from stents
JP4606027B2 (en) * 2002-04-03 2011-01-05 トポターゲット ユーケー リミテッド Carbamate compounds having piperazine bonds as HDAC inhibitors
JP4617449B2 (en) * 2002-07-11 2011-01-26 ヴィキュロン ファーマシューティカルズ インコーポレイテッド N-hydroxyamide derivative having antibacterial activity
WO2011092284A1 (en) * 2010-01-29 2011-08-04 Euroscreen S.A. Novel amino acid derivatives and their use as gpr43 receptor modulators
CN104211695B (en) * 2013-06-04 2017-04-12 中国医学科学院医药生物技术研究所 Use of group of carbamyl phenylsulfonyl compounds
US20180000817A1 (en) * 2015-01-15 2018-01-04 Biocant - Associação De Transferência De Tecnologia Treatment of hutchinson-gilford progeria syndrome and diseases related to vascular ageing
CN106831697B (en) * 2017-03-15 2019-11-05 深圳市康道生物有限公司 The effective extract component of river hazel and its application in prevention and treatment atherosclerosis

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5366987A (en) * 1991-08-22 1994-11-22 Warner-Lambert Company Isoxazolyl-substituted alkyl amide ACAT inhibitors
US5491172A (en) * 1993-05-14 1996-02-13 Warner-Lambert Company N-acyl sulfamic acid esters (or thioesters), N-acyl sulfonamides, and N-sulfonyl carbamic acid esters (or thioesters) as hypercholesterolemic agents
CN1192140A (en) * 1995-08-04 1998-09-02 沃尼尔·朗伯公司 Use of sulfamic acid derivatives, acyl sulfonamides or sulfonyl carbamates for the manufacture of a medicament for lowering lipoprotein levels
KR20000011095A (en) * 1996-05-17 2000-02-25 로즈 암스트롱, 크리스틴 에이. 트러트웨인 Nonphenyl sulfoneamide as inhibitor of matrix metalloproteinase
WO1998009934A1 (en) * 1996-09-04 1998-03-12 Warner-Lambert Company Matrix metalloproteinase inhibitors and their therapeutic uses

Also Published As

Publication number Publication date
ID30030A (en) 2001-11-01
WO2000004892A3 (en) 2000-05-18
HRP20010055A2 (en) 2002-04-30
HUP0102880A3 (en) 2002-11-28
ZA200100294B (en) 2002-01-10
CZ2001126A3 (en) 2002-01-16
EA200100153A1 (en) 2001-08-27
CN1310629A (en) 2001-08-29
NO20010291L (en) 2001-01-18
AU4701799A (en) 2000-02-14
IS5809A (en) 2001-01-12
WO2000004892A2 (en) 2000-02-03
IL140982A0 (en) 2002-02-10
BR9912296A (en) 2001-04-17
KR20010083134A (en) 2001-08-31
EE200100046A (en) 2002-06-17
JP2002521328A (en) 2002-07-16
CA2335062A1 (en) 2000-02-03
PL346011A1 (en) 2002-01-14
SK502001A3 (en) 2002-06-04
TR200100205T2 (en) 2001-05-21
OA11584A (en) 2004-07-20
AP2001002035A0 (en) 2001-03-31
NO20010291D0 (en) 2001-01-18
HUP0102880A2 (en) 2002-06-29
BG105162A (en) 2001-12-29
EP1098662A2 (en) 2001-05-16

Similar Documents

Publication Publication Date Title
YU3501A (en) Coadministration of acat and mmp inhibitors for the treatment of atherosclerotic lesions
AU2713600A (en) Use of a matrix metalloproteinase inhibitor and an integrin antagonist in the treatment of neoplasia
ZA200104118B (en) Substituted benzimidazoles and their use as PARP inhibitors.
PT1011682E (en) HORMONAL CONTRACEPTIVE
WO2002003978A3 (en) A COMBINATION OF FBPase INHIBITORS AND ANTIDIABETIC AGENTS USEFUL FOR THE TREATMENT OF DIABETES
GB9804886D0 (en) Therapeutic combination
HK1038198A1 (en) Use of eletriptan in the manufacture of a medicament for the prevention of migraine recurrence.
AU3364899A (en) Peripheral-type benzodiazepine receptor: a tool for detection, diagnosis, prognosis, and treatment of cancer
MXPA01005165A (en) Dual mode emergency braking apparatus and method of use thereof.
CY1108053T1 (en) UNION OF CYAMEMAZINE AND A FORMULATED NEUROLIPTIC
AU2002230390A1 (en) Ixodes scapularis tissue factor pathway inhibitor
HK1033876A1 (en) Use of nmda antagonists for treatment of irritablebowel syndrome.
NO20012569D0 (en) Use of aryl-substituted cyclobutylamines for the treatment of urinary incontinence
WO1999002565A3 (en) Agent for the treatment and/or prophylaxis of microcirculation disorders
IT1302813B1 (en) DEVICE FOR THE DIRECT REDUCTION OF IRON OXIDES AND RELATED PROCEDURE
DE29808968U1 (en) Panty liner or menstrual pad
AU4144099A (en) Use of an agent for the prevention of gum disease
GB0029207D0 (en) Brake shoe and internal shoe drum brake
GB9824875D0 (en) Use of an agent for the prevention of gum disease
DE29807623U1 (en) Socket and contact for the socket
AU7419501A (en) Use of riluzole or its salts for preventing and treating adrenoleukodystrophy
TW374520U (en) Increasing and deducting structure for the metal guide foot of the computer line terminals
SI1100499T1 (en) Use of eletriptan for the prevention of migraine recurrence